title: Acetyl-L-carnitine corrects the altered peripheral nerve function of experimental diabetes.
abstract: Acetyl-L-carnitine (ALC) has been shown to facilitate the repair of transected sciatic nerves. The effect of ALC (50 mg/kg/d) on the diminished nerve conduction velocity (NCV) of rats with streptozotocin (STZ)-induced hyperglycemia of 3 weeks' duration was evaluated. The aldose reductase inhibitor, sorbinil, which is reported to normalize the impaired NCV associated with experimental diabetes, was used as a positive control. Aldose reductase inhibitors are thought to have an effect by decreasing peripheral nerve sorbitol content and increasing nerve myo-inositol. Treatment of STZ-diabetic rats with either ALC or sorbinil resulted in normal NCV. Sorbinil treatment was associated with normalized sciatic nerve sorbitol and myo-inositol; ALC treatment did not reduce the elevated sorbitol levels, but sciatic nerve myo-inositol content was no different from nondiabetic levels. Both ALC and sorbinil treatment of STZ-diabetic rats were associated with a reduction in the elevated malondialdehyde (MDA) content of diabetic sciatic nerve, indicating reduced lipid peroxidation. The beneficial effects of sorbinil and ALC on the altered peripheral nerve function associated with diabetes were similar, but their effects on the polyol pathway (frequently implicated in the pathogenesis of peripheral neuropathy) were different.
authors.affiliation: Department of Pediatrics, University of South Florida, Tampa, USA.
authors.forename: S
authors.initials: S
authors.lastname: Lowitt
authors.forename: J I
authors.initials: JI
authors.lastname: Malone
authors.forename: A F
authors.initials: AF
authors.lastname: Salem
authors.forename: J
authors.initials: J
authors.lastname: Korthals
authors.forename: S
authors.initials: S
authors.lastname: Benford
mesh_terms: D000108:Acetylcarnitine / Q000627:therapeutic use*; D000449:Aldehyde Reductase / Q000037:antagonists & inhibitors; D000818:Animals; D003921:Diabetes Mellitus, Experimental / Q000503:physiopathology*; D003929:Diabetic Neuropathies / Q000188:drug therapy* / Q000503:physiopathology; D007093:Imidazoles / Q000627:therapeutic use; D048289:Imidazolidines; D008297:Male; D018482:Muscle, Skeletal / Q000294:innervation; D009431:Neural Conduction / Q000187:drug effects; D051381:Rats; D017208:Rats, Wistar; D012584:Sciatic Nerve / Q000187:drug effects / Q000502:physiology / Q000503:physiopathology*
chemical_list: D007093:Imidazoles; D048289:Imidazolidines; D000108:Acetylcarnitine; D000449:Aldehyde Reductase; C026411:sorbinil